Immuneering Stock Rises 21.7% on Supply Agreement With LLY

Immuneering Corporation (IMRX) shares rose 21.7% after announcing a clinical supply agreement with Eli Lilly (LLY) to evaluate Immuneering's lead candidate, atebimetinib, in combination with Lilly's olomorasib in a planned Phase II study for advanced KRAS G12C-mutant non-small cell lung cancer. This partnership, Immuneering's second major collaboration in 2025, highlights the company's strategy to advance atebimetinib through combination therapies while retaining full development and commercialization rights, buoyed by preclinical data suggesting enhanced tumor regression and delayed resistance. The significant year-to-date stock performance of +170.5% reflects investor confidence in these strategic alliances and the potential of its oncology pipeline.

Analysis

Immuneering Corporation (IMRX) experienced a significant 21.7% stock price increase following the announcement of a clinical supply agreement with Eli Lilly (LLY). This partnership will evaluate Immuneering's lead candidate, atebimetinib, in a phase II study with Lilly’s olomorasib for KRAS G12C-mutant non-small cell lung cancer. The agreement represents crucial external validation for atebimetinib and highlights a capital-efficient development strategy, as it follows a similar deal with Regeneron in February 2025. In both collaborations, Immuneering retains full worldwide commercialization rights, preserving maximum potential upside while leveraging partners' assets. The market's positive reaction is underscored by the stock's 170.5% year-to-date gain, far outpacing the industry's 4.1% rise. This momentum is further supported by promising early data from a separate phase IIa study in pancreatic cancer, which showed a 94% overall survival and 72% progression-free survival at six months, with updated data expected in Q3 2025. As a pre-revenue company, these pipeline advancements and strategic partnerships are the primary drivers of its valuation.

Key Decisions for Investors

• The dual partnerships with Eli Lilly and Regeneron provide significant scientific validation for atebimetinib, but investors must weigh this against the substantial 170.5% year-to-date stock appreciation which may have priced in much of this positive news.
• The primary near-term catalyst to monitor is the updated overall and progression-free survival data from the separate pancreatic cancer study, expected in the third quarter of 2025, as strong results would further de-risk the asset.
• Recognize that while Immuneering retains full commercial rights, it also bears the full financial and clinical risk of these trials, making the stock a high-risk, high-reward investment entirely dependent on future clinical outcomes.